Nuvilex (NASDAQ:PMCB) Announces Quarterly Earnings Results, Misses Estimates By $0.48 EPS

Nuvilex (NASDAQ:PMCB) released its quarterly earnings results on Monday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.48), FiscalAI reports.

Nuvilex Price Performance

Shares of PMCB opened at $0.38 on Wednesday. The stock’s 50-day moving average is $0.56 and its two-hundred day moving average is $0.68. The stock has a market cap of $4.11 million, a PE ratio of -0.17 and a beta of 0.66. Nuvilex has a 12 month low of $0.33 and a 12 month high of $1.51.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 2nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.